Skip to content
Companies

Georgiamune

Immune-reprogramming antibodies for cancer and autoimmunity

Raised to date

$92.7M

of $131.9M offered across 1 Form D filing

Still open
$39.2M
Investors
26
Last filed
Aug 17, 2026

About

Georgiamune is a clinical-stage immunotherapeutics company in Gaithersburg, Maryland, founded by Dr. Samir Khleif to reprogram immune signaling pathways so the immune system attacks cancer or stands down in autoimmune disease. Its pipeline pairs dual-functioning monoclonal antibodies with immune-reprogramming small molecules, led by GIM-122, GIM-531 and GIM-407. The company cleared an FDA IND for GIM-122 and raised a $75M Series A in 2023, and moved three assets into clinical trials in 2024. Additional discovery and IND-enabling programs (GIM-616, GIM-710 and others) remain undisclosed.

Targets immune signaling reprogramming rather than a single checkpoint, with dual-functioning antibodies aimed at overcoming resistance to existing immunotherapy and paired small molecules that either inhibit or activate T-regulatory cells depending on whether the goal is oncology or autoimmunity.

Funding

  • EquityFiled Aug 17, 2026Form D
    $92.7M/ $131.9M

Product

GIM-122

Oncology biologic

A first-in-class dual-functioning monoclonal antibody developed to overcome resistance to immunotherapy in cancer patients; it received FDA clearance of its Investigational New Drug application in 2023.

  • Dual-functioning monoclonal antibody
  • Aimed at immunotherapy-resistant cancers
  • FDA IND clearance obtained

Built for

Patients with immunotherapy-resistant cancers and with autoimmune disease, reached through oncologists and, ultimately, pharmaceutical partners or acquirers who commercialize approved therapies

People on file